Today: 29 April 2026
Browse Category

TSX:CRON 12 December 2025

Cronos Group Inc (CRON) Stock Surges as US Marijuana Rescheduling Buzz Returns — Latest News, Forecasts, and Key Catalysts (Dec. 12, 2025)

Cronos Group Inc (CRON) Stock Surges as US Marijuana Rescheduling Buzz Returns — Latest News, Forecasts, and Key Catalysts (Dec. 12, 2025)

Cronos Group shares jumped as much as 19% in premarket trading Dec. 12 after reports that President Trump may seek to reclassify marijuana as a Schedule III drug. Reuters and other outlets cited broad gains across cannabis stocks on the news. Cronos recently announced a strategic acquisition in the Netherlands, aiming for top market share in Europe's largest adult-use market. No final decisions on U.S. policy have been confirmed.
12 December 2025
··
Cronos Group Inc (CRON) Stock Surges as US Marijuana Rescheduling Buzz Returns — Latest News, Forecasts, and Key Catalysts (Dec. 12, 2025)

Cronos Group Inc (CRON) Stock Surges as US Marijuana Rescheduling Buzz Returns — Latest News, Forecasts, and Key Catalysts (Dec. 12, 2025)

Cronos Group shares jumped as much as 19% in premarket trading December 12 after reports said the Trump administration may seek to reclassify marijuana as a Schedule III drug. The move follows Cronos’ recent acquisition in the Netherlands, aimed at securing top market share in Europe’s largest adult-use cannabis market. No final U.S. policy decisions have been made.
12 December 2025
·

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 3:00 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop